Dataset from A Qualitative Hybrid III Implementation Study to Identify and Evaluate Strategies for Successful Implementation of the Cabotegravir + Rilpivirine Long-acting Injectable Regimen in the US

Chronic human immunodeficiency virus (HIV) infection in adults continues to be characterized
by increased development of resistant virus, increased transmission of resistant virus and
issues associated with the long-term toxicity of anti-retroviral therapy (ART), despite
advances in development of new ART, which provides extensive insight in management of
HIV-infected individuals. Cabotegravir (CAB) is a potent integrase inhibitor (INI) and
rilpivirine (RPV) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI). A
two-drug regimen (DR)with CAB plus RPV long acting (LA) product offers many potential
advantages over daily oral regimens including better tolerability, improved compliance,
adherence, less likely to develop resistance, and overall treatment satisfaction in
virologically suppressed subjects. This is a single-arm, open-label, multicenter, short term
facilitation study to evaluate the effect of an implementation strategy on the degree of
acceptability, appropriateness, feasibility, fidelity and sustainability of clinical
practices to deliver the CAB+RPV LA regimen to HIV infected subjects and to also measure
subject satisfaction by recording timeliness of visits, length of visit and their education.
Approximately 135 subjects will be enrolled in the study and the total duration of the study
will be approximately 52-weeks.